

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

nothy A Blizzard et al.

Serial No.

Filed:

To be assigned

10/579,652

Art Unit:

To be assigned

Examiner:

To be assigned

ESTROGEN RECEPTOR MODULATORS

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

May 18, 2006

INFORMATION DISCLOSURE STATEMENT **UNDER 37 CFR 1.97**

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

on Date 07-27-06

INFORMATION DISCLOSURE STATEMENT

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

	RELATED APPLICATION				
U. S. SERIAL NUMBER	FILING DATE	MERCK CASE			

If th	is is inconvenient, additional copies will be submitted upon request.
6	5. In accordance with 37 C.F.R. 1.97, (check one)
\checkmark	the attached information is filed within three months of the filing date of the captioned case.
	the attached information is filed more than three months after the filing date but prior to the mailing of a first Office Action on the merits.
	the attached information is filed before the mailing of a first Office action after the filing of a request for continued examination under §1.114.
	the attached information is being filed more than three months after the filing date and after the mailing of a first Office Action on the merits, but before the mailing date of a Final Action, Notice of Allowance, or an action that otherwise closes prosecution in the application. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
	each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
	each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of the information disclosure statement.
	no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of this Statement.
	Respectfully submitted,

By: Dianne Brown

<u>Attorney</u> For Applicant(s)

Reg. No. 42,068

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-1249

Date: July 27, 2006

						Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
	Substitute f	or form 1449A/PTO				COMPLETE IF KNOWN
	INFO	RMATION	DIS	CLOSURE	Application Number	To be assigned
	E STAT	TENATENET DX	7 A TO	DI ICANIT	Filing Date	May 18, 2006
6	E STATEMENT BY APPL		PLICANI	First Named Inventor	Timothy A. Blizzard	
ונ	3 1 2006 E	,		,	Group Art Unit	To be assigned
/ 30		e as many sheet	s as n	ecessary)	Examiner Name	To be assigned
FREN	4.Shace	1	of	2	Attorney Docket Number	21441YP
						

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	
		3,101,357		Syntex Corporation	08/20/1963	
		4,882,322		Merrell Dow Pharmaceuticals, Inc.	11/21/1989	
		3,102,107		Hercules Powder Company	08/27/1963	

Office	Foreign Patent Docume Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	Number	Code		
1				
1		<u> </u>		
 				-
 				

Examiner Signature Date Considered					
	Examiner				

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE
Substitute for form 1449B/PTO			COMPLETE IF KNOWN
INFORMATION DIS	CLOSURE	Application Number	To be assigned
E STM TEMENT DV AD	DI ICANIT	Filing Date	May 18, 2006
E STATEMENT BY AP	FLICANI	First Named Inventor	Timothy A. Blizzard
(usp as many sheets as n	,	Group Art Unit	To be assigned
\	secessary)	Examiner Name	To be assigned
Sheet of 2 of	2	Attorney Docket Number	21441YP
<u> </u>	•		

		NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
		Adami, S, Cancer Supplement (1997), Vol. 80, No. 8, pp 1674-1679, "Bisphosphonates in Prostate Carcinoma"
		· · · · · · · · · · · · · · · · · · ·
	_	

Examiner	Date	
Signature	 Considered -	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.